Contrasting Becton, Dickinson and Company (NYSE:BDX) & NeuroOne Medical Technologies (NASDAQ:NMTC)

Becton, Dickinson and Company (NYSE:BDX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Becton, Dickinson and Company and NeuroOne Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	0	6	5	0	2.45
NeuroOne Medical Technologies	0	0	1	0	3.00

Becton, Dickinson and Company currently has a consensus price target of $231.44, indicating a potential upside of 31.97%. NeuroOne Medical Technologies has a consensus price target of $1.45, indicating a potential upside of 118.05%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Becton, Dickinson and Company.

Insider and Institutional Ownership

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 8.9% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Becton, Dickinson and Company has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Valuation and Earnings

This table compares Becton, Dickinson and Company and NeuroOne Medical Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$20.87 billion	2.41	$1.71 billion	$5.24	33.47
NeuroOne Medical Technologies	$5.75 million	5.48	-$12.32 million	($0.26)	-2.56

Becton, Dickinson and Company has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Becton, Dickinson and Company and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	8.47%	15.74%	7.29%
NeuroOne Medical Technologies	-82.17%	-270.70%	-129.70%

Summary

Becton, Dickinson and Company beats NeuroOne Medical Technologies on 9 of the 14 factors compared between the two stocks.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.